Evox Therapeutics Partners with Rett Syndrome Research Trust to Advance ExoEdit Gene Editing Platform for Neurological Disease
Key Insights
Evox Therapeutics (search) has initiated a collaboration with the Rett Syndrome Research Trust to evaluate its ExoEdit (search) exosome-based delivery platform for developing gene editing treatments for Rett syndrome (search).
The partnership aims to address the critical challenge of safe and efficient gene editing delivery to the central nervous system for treating this severe neurodevelopmental disorder (search).
Over 90% of Rett syndrome (search) cases are caused by mutations in the MECP2 (search) gene, making it a prime target for gene editing approaches that could potentially reverse symptoms even after disease onset.
Evox Therapeutics (search) Ltd announced a new collaboration with the Rett Syndrome Research Trust (RSRT) to assess the feasibility of using the company's ExoEdit (search) exosome-based delivery platform for developing gene editing treatments for Rett syndrome (search). The partnership represents a significant step toward addressing one of the most challenging aspects of gene editing therapy: safe and efficient delivery to the central nervous system.
Addressing Critical Delivery Challenges
The collaboration focuses on overcoming what has been identified as a major obstacle in gene editing therapy for neurological conditions. "Gene editing offers the possibility of correcting the mutations responsible for Rett syndrome (search) and potentially reversing symptoms even after disease onset, though safe and efficient delivery to the central nervous system remains a key challenge," said Per Lundin, PhD, Co-founder and Chief Executive Officer of Evox.
Monica Coenraads, Founder and Chief Executive Officer of RSRT and parent of an adult daughter with Rett syndrome (search), emphasized the significance of the delivery challenge: "Non-viral delivery to the brain has long been a major obstacle to establishing gene editing as a therapy for Rett syndrome. We see great potential in Evox's ExoEdit (search) technology to efficiently and safely deliver editing cargo throughout the brain."
Targeting MECP2 Gene Mutations
Rett syndrome (search) is a severe genetic neurodevelopmental disorder (search) that predominantly affects girls and is typically diagnosed between the ages of 12 to 18 months. The condition presents with a wide spectrum of clinical manifestations, with the most common including loss of speech and purposeful hand use. Patients may also lose the ability to walk, have difficulty breathing and experience gastrointestinal issues.
Over 90% of Rett syndrome (search) cases are caused by mutations linked to the methyl-CpG-binding protein 2 (MeCP2 (search)) gene, which is essential for neuronal function. This genetic basis makes the condition a prime target for gene editing approaches. If the current collaboration proves successful, the findings could establish the foundation for an expanded preclinical program targeting the large majority of Rett syndrome patients whose disease is caused by MECP2 gene mutations.
Current Treatment Landscape and Unmet Needs
Presently, there is no cure for Rett syndrome (search), and treatment utilizes a multidisciplinary approach that may include physical therapy, speech therapy, and occupational therapy in addition to medications for certain symptoms. The condition profoundly impairs motor function, speech, and breathing, often requiring lifelong, around-the-clock care and specialized teams to manage complex, multi-system symptoms.
Broader Research Initiative Context
The collaboration comes as part of RSRT's broader commitment to advancing genetic medicines for Rett syndrome (search). The organization is the largest funder of Rett research worldwide, and multiple clinical trials in gene therapy for Rett syndrome are currently underway, all made possible through RSRT-funded research. In 2024, RSRT launched a $40 million initiative called Roadmap to Cures, with a goal to bring three genetic medicines, beyond the current gene therapies, to clinical trials by 2028.
Evox's Gene Editing Pipeline
Evox Therapeutics (search) is developing a pipeline of next-generation gene editing medicines with a mission to revolutionize the treatment of genetically driven neurodegenerative diseases. The company's current pipeline programs target the MSH3 (search) gene for the treatment of Huntington's disease (search) and other trinucleotide repeat disorders, and the ATXN2 (search) gene for the treatment of amyotrophic lateral sclerosis (search) and other TDP43 pathologies.
The ExoEdit (search) platform represents the company's approach to addressing delivery challenges that have historically limited the application of gene editing technologies in neurological conditions. "Our ExoEdit technology has the potential to enable gene editing medicines to safely and effectively reach the brain, making it possible to leverage gene editing to correct the root causes of devastating neurological diseases such as Rett syndrome (search)," Lundin explained.
The collaboration with RSRT marks an important expansion of Evox's focus into Rett syndrome (search), potentially opening new clinical pathways for patients with this devastating condition.